🚀 Proud to launch my iOS app for cardiac amyloidosis diagnosis & research updates. Built on my Swift coding foundations laid at @csmbulldogs. 📱 Download now: Looking forward to your feedback and support!.#CardiacAmyloidosis #HealthTech #MedTwitter

Full video 🎊🙏.

An unique opportunity thanks to @ZeeNews 🙏

"Wait, since I'm an AI, I can't actually check the video". Grok coming to realization that it is an AI was the highlight for me today! 😂.

In the mean time if someone needs a part time coder, hit me up!

In some good news, I will be joining Emory University as a heart failure cardiologist in the fall.

Mom books are more like: 'Unlocking Neuroplasticity in Infants.' .Meanwhile dad books: 'Don't Forget Diapers, Dude.'".

RT @ParijatSen11: If you are someone who rounds in a multi disciplinary ICU and thinks of strategies to elevate it to the next level, pleas….

The most intimidating and gratifying thing is to see your name listed as the attending on the patient's chart. .

I was taken aback to see a Shivsena supporter in the parking lot today. Later realized that's Chicago 'Bears' 😅

Why do they call it animal 'husband'ry?.P.S. Do not ask your wife!.

It is always RV failure 😅.

Spotted Doordarshan in the hospital today. Now the song is in my head! Mile sur mera tumhara.

You don't realize how difficult it is to sleep in the hospital until you come as a patient or a relative. .

RT @nakeya52: And we are published! @hasbeenHuzefa @AbdulMannan5465 @KhadijaAman @DmitryAbramovMD @SaurabhSDani @G….

How are the cars planning on coming out! 😅

The simple pleasure of having panipuri. !.

RT @BudoffMd: @Gaurang_MD When neither arm works as expected, you have to suspect something wrong with the trial itself. EPHESUS trial fou….

7. The OPTION trial compared LA appendage closure to oral anticoagulation for stroke prevention in select post-ablation afib patients and found it to be a viable alternative, while reducing bleeding risk. Came across a debate on this however:

6. The HELIOS-B trial showed vutrisiran, an RNA 'silencer' agent, reduced outpatient worsening HF, all-cause mortality, and recurrent CV events in ATTR-CM patients. This subcutaneous therapy could be a game-changer for #ATTR cardiomyopathy!.@Alnylam

5. Lipoprotein(a) emerged as a significant focus at #AHA24. It is gaining recognition as a crucial CV risk marker independent of LDL and there was a booth to get yours checked!.Muvalaplin achieved Lp(a) reductions of up to 86%. Another promising Rx, zerlasiran, showed positive.